Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Accumulated Depreciation & Amortization (2016 - 2026)

Gyre Therapeutics has reported Accumulated Depreciation & Amortization over the past 12 years, most recently at $7.6 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 35.31% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 35.31% year-over-year, with the annual reading at $7.6 million for FY2025, 35.31% up from the prior year.
  • Accumulated Depreciation & Amortization was $7.6 million for Q4 2025 at Gyre Therapeutics, up from $6.9 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $7.6 million in Q4 2025 and troughed at $4.0 million in Q4 2022.
  • The 4-year median for Accumulated Depreciation & Amortization is $5.5 million (2024), against an average of $5.6 million.
  • Year-over-year, Accumulated Depreciation & Amortization increased 6.68% in 2023 and then surged 35.31% in 2025.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $4.0 million in 2022, then increased by 6.68% to $4.3 million in 2023, then skyrocketed by 31.28% to $5.6 million in 2024, then surged by 35.31% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Accumulated Depreciation & Amortization are $7.6 million (Q4 2025), $6.9 million (Q3 2025), and $6.4 million (Q2 2025).